Taking Initiative

To address these priorities, the Global CEO Initiative has formed four Working Groups co-led by a corporate member of the Global CEO Initiative and a leading non-governmental partner, exemplifying the collaborative and partnership orientation that lies at the core of the CEOi. Each of the Working Groups is executing a comprehensive work plan with specific goals and metrics that are reviewed regularly by all members of the Global CEO Initiative and by the Federal Advisory Council on Research, Care and Services created by the National Alzheimer’s Project Act.

Research Working Group

Co-led by Sanofi SA and the New York Academy of Sciences, this working group is complementing existing efforts to develop and advance a prioritized comprehensive research agenda, one that is informed by all parties including government, academia and industry. A major undertaking is a planned June 2013 research summit to be hosted by the Academy designed to continue the actions begun in 2012 by the National Institute on Aging Alzheimer's Disease Summit. The 2013 research summit will bring together a broad set of Alzheimer's stakeholders, including academia, industry, patient advocates, and governmental leaders, to produce an agreed upon set of research priorities that will inform all Alzheimer's research efforts, including resource allocation, moving forward.

Pipeline Compression

Co-led by Janssen Pharmaceuticals, a division of Johnson & Johnson, and the Critical Path Institute's Coalition Against Major Diseases (CAMD), this group is focusing on ways to reduce the time, cost and risk in developing therapies and treatments, particularly those for Alzheimer's disease and dementia. The scope of issues before the working group is wide-ranging, including:

  • Establishing common data standards to facilitate scientific collaborations and accelerate FDA review of drug applications;
  • Achieving breakthroughs in developing and qualifying Alzheimer's disease biomarkers;
  • Developing robust patient registries to accelerate clinical trial recruitment; and
  • Expanding access to clinical trial data to prevent duplicative research, reduce unnecessary costs and risks and accelerate the pace of development of therapies and treatments.

Clinical Trial Enrollment

Closely related to the Pipeline Compression Working Group, this effort will be led by Banner Health and the Banner Alzheimer's Institute. Banner Health will lead the effort to develop a robust and well-defined patient registry to expedite the often slow and costly process of recruiting and enrolling patients in clinical trials.

Awareness Raising & Stigma Reduction

Co-led by Eli Lilly and Company, Bank of America and the National Council on Aging, this group is working to bolster existing government and non-governmental awareness-raising and stigma-reduction efforts to encourage those showing symptoms of cognitive or other brain impairment – and their caregivers – to seek medical advice and a diagnosis as well as other supportive services. By keying into the "value of knowing," this effort ultimately aims to improve the quality of life for all those affected by Alzheimer’s and other dementias through ensuring access to quality care and services.